Your immune system has a built-in brake — scientists just learned how to use it

Researchers at University College London (UCL) have uncovered a natural mechanism that tells the immune system when to stand down. Published in Nature Communications, the study identifies a group of fat-derived molecules called epoxy-oxylipins as key players in shutting down inflammation — a finding that could reshape how we treat chronic inflammatory diseases.

In a controlled human trial, healthy volunteers received a tiny injection of UV-killed E. coli bacteria to trigger a temporary inflammatory response. Participants were then given a drug (GSK2256294) that blocks the enzyme soluble epoxide hydrolase (sEH) — which normally destroys epoxy-oxylipins — allowing more of these protective molecules to accumulate. The result: pain resolved faster and levels of harmful intermediate monocytes (immune cells linked to chronic inflammation) dropped significantly, both in blood and tissue. The team traced the effect to a specific molecule, 12,13-EpOME, which suppresses a signaling pathway (p38 MAPK) that drives the buildup of these problematic immune cells.

Key Takeaways:

• Unlike current anti-inflammatory drugs that broadly suppress immunity, this approach enhances a natural shutdown process — potentially reducing side effects
• The drug used is already suitable for human use and could be repurposed for conditions like rheumatoid arthritis
• Clinical trials testing sEH inhibitors in chronic inflammatory diseases are a likely next step

Why it matters: Chronic inflammation underlies some of the world's most common and debilitating conditions — from arthritis to heart disease to diabetes. A therapy that restores immune balance without compromising the body's defenses could be a game-changer for millions of patients.